USFDA accepts AstraZeneca’s BLA for nirsevimab to prevent RSV lower respiratory tract disease EP News Bureau Jan 6, 2023 Nirsevimab is being developed and commercialised by AstraZeneca in collaboration with Sanofi, and is the first single-dose…
Sanofi and AstraZeneca win EU approval for prevention of infant RSV Reuters Nov 7, 2022 The long-acting therapy, also known as nirsevimab, was given the European Union (EU) marketing authorisation for the prevention of…
Nirsevimab gets Promising Innovative Medicine Designation from MHRA EP News Bureau Jan 19, 2021 Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
